Company Overview#
MEDIAIPLUS is a healthcare data company that builds a clinical trial intelligence platform. The company addresses the inefficiencies in clinical trial preparation and the difficulty of finding the right contract research organization (CRO). By aggregating and processing global clinical trial data, MEDIAIPLUS provides actionable insights to biotech firms, CROs, researchers, and patients.
Technology & Product#
The core product is MediC, a global clinical trial information service. MediC allows users to search clinical trial data, organize information, and track the latest regulations and trial designs. MEDIAIPLUS also operates FiCRO, a sponsor-CRO matching service that connects drug developers with suitable CROs, offering automated matching, notifications, and digital RFP management.
Market & Use Cases#
The primary market consists of early-stage pharmaceutical and biotech companies preparing for clinical trials. These companies use MediC to obtain customized reports on drug patents, clinical trial designs, and regulatory insights. The FiCRO service targets sponsors who need to efficiently select and manage CROs for their clinical trials.
Traction & References#
MediC provides a database built on over 700,000 processed and annotated clinical trial records globally. As of February 2026, FiCRO has secured a database of more than 29,700 CROs worldwide(Hankyung). The company reports that the platform cuts clients’ clinical preparation time from roughly six months to about ten days, with significant cost savings. The company holds CDISC Platinum certification and participated in the NEMIC healthtech accelerator program in the US in 2023. MEDIAIPLUS was also selected for the TIPS program and the IBK Changgong innovation program, and won an excellence award from the Korea Data Agency (K-DATA).
Collaboration Relevance#
MEDIAIPLUS is relevant for biotech companies seeking data-driven insights for clinical trial design and efficient CRO selection. It is also suitable for global CROs looking to connect with Korean drug developers. Pharmaceutical companies can leverage the MediC platform for regulatory insights and competitive intelligence during the early stages of drug development.